EGFR is an oncogene commonly overexpressed in breast cancer. It is associated with unfavourable prognosis. Drug resistance against tyrosine kinase inhibitors is a major drawback in the current line of treatment. Phytochemicals from Holarrhena antidysentrica were used for molecular based drug designing to target L858R mutation of EGFR leading to higher efficacy with minimal side effects. Molecular docking facilitates study of molecular and structural diversity in an organised manner. Using curated databanks, 150 phytochemicals were identified from the plant of interest and 52 compounds passed the SwissADME test for drug likeness. The phytochemicals were targeted against the native and mutant structure of EGFR retrieved from PDB. The identified phytochemicals to combat L858R mutation revealed 2 compounds including naringenin-7-glucoside that showed a good dock score and fit value as the novel outcome. It is found out that the naringenin-7-glucoside can act as an active antidote to breast.